Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Key Points

• Maravai LifeSciences saw a substantial increase in put options trading, with 1,002 put options purchased, marking a 1,791% surge compared to its typical daily volume of 53.
• Institutional investors now own 50.25% of Maravai LifeSciences, with several firms recently acquiring new stakes in the company.
• Equities analysts have lowered price targets for Maravai LifeSciences, with the consensus rating being "Hold" and an average target price of $5.22.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) saw unusually large options trading activity on Wednesday. Stock investors acquired 1,002 put options on the stock. Thisrepresentsanincreaseofapproximately1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Trading Down 2.2%

Shares of NASDAQ:MRVI traded down $0.06 during midday trading on Monday, reaching $2.46. 277,415 shares of the company's stock were exchanged, compared to its average volume of 2,304,152. The firm's 50 day simple moving average is $2.49 and its two-hundred day simple moving average is $2.35. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The stock has a market cap of $626.91 million, a price-to-earnings ratio of -1.81 and a beta of 0.29. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $9.50.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently bought and sold shares of MRVI. ProShare Advisors LLC boosted its stake in shares of Maravai LifeSciences by 89.8% in the 4th quarter. ProShare Advisors LLC now owns 55,488 shares of the company's stock valued at $302,000 after buying an additional 26,251 shares during the period. Nuveen LLC acquired a new position in Maravai LifeSciences during the first quarter worth approximately $666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Maravai LifeSciences by 22.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company's stock worth $1,369,000 after buying an additional 45,454 shares during the period. SG Americas Securities LLC increased its position in Maravai LifeSciences by 2,005.9% during the first quarter. SG Americas Securities LLC now owns 695,907 shares of the company's stock worth $1,538,000 after buying an additional 662,861 shares during the period. Finally, Northern Trust Corp boosted its position in Maravai LifeSciences by 5.3% during the fourth quarter. Northern Trust Corp now owns 1,070,425 shares of the company's stock worth $5,834,000 after purchasing an additional 53,474 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several recent research reports. Robert W. Baird lowered their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Craig Hallum decreased their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada decreased their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Three research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $5.22.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.